Drugs / Autologous Adipose Derived Mesenchymal Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02808208 | Jun 2017 → Dec 2026 expected | end stage renal failure | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adipose Derived Mesenchymal Stem Cells | “Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)” NCT02808208 ↗ |
| Known as | AMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02808208 ↗ |
| Modality | Cell therapy | “autologous adipose-derived mesenchymal stem cells delivered locally” PMID 35419530 ↗ Sep 2021 |
| Route | Topical | “A single topical application of mesenchymal stem cells derived from own fat biopsy” NCT02808208 ↗ |